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Aim. The purpose of this study was to evaluate the effectiveness of cryopreserved arterial allografts in the management of
prosthetic graft infection.
Material and methods. Over a 5-year period 45 patients with infection of prosthetic vascular grafts were treated. There
were 39 intra-abdominal infected grafts (group I) and six extra-abdominal infected grafts (group II). Treatment consisted of
total graft removal and in situ or extra-anatomic implantation of cryopreserved arterial allografts. Six patients were
operated on as an emergency. Four patients presented with aorto-enteric fistula. Follow-up ranged from 30 to 78 months.
Results. There were six in-hospital deaths and two additional patient deaths during follow-up, yielding an overall mortality
rate of 18%. Six patients died due to complications directly related to infection or insertion of an allograft. Combined short
and long-term mortality rate was much higher in patients operated on as an emergency (67%) compared to elective cases
(11%). Patients with aorto-enteric fistula had the highest mortality rate (75%). Primary and secondary 3-year allograft
patency rates for group I were 84 and 94%, respectively and for group II were 60 and 80%, respectively.
Conclusions. Aortic allografts are useful in the treatment of infection of major vascular prosthetic grafts, except for patients
with aorto-enteric fistula. Patients with infection of the prosthetic graft should be promptly assessed for graft removal, since
results of elective surgery are much better than results of emergency procedures.
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Introduction
The progress in medical sciences, including adequate
preparation of patients, perioperative antibiotic pro-
phylaxis, shorter duration of procedures and mini-
misation of blood loss associated with implantation of
vascular prosthetic grafts has led to a decrease in the
incidence of vascular graft infection. An incidence of
2.1% for graft infection, reported in the 1960s,1 has
fallen to 1.1% in recent reports.2 Significant progress
also has been achieved in the treatment of infections of
major vascular prosthetic grafts. This is mainly a result
of reserving local treatment only for stages I and II
infection, categorized according to Samson and Veith
classification.3 Total removal of the graft for stage III–
V infection, has become the principle of treatment,
especially for Dacron grafts and those with positive
bacteriological cultures.4 However, removal of the
graft creates a problem of pelvic and limb ischaemia.
The study by Quinones-Baldrich et al. showed the
advantage of performing vascular reconstruction
along with removal of the graft.5 They observed a
reduction in mortality from 40% in patients without
vascular reconstruction to 16% in patients in whom
concomitant vascular reconstruction was performed.
However, unequivocal data regarding the efficacy of
different surgical methods for restoration of blood
flow to the lower extremities is lacking.6 The purpose
of this study was to analyse the results of treatment of
infected vascular prosthetic grafts with cryopreserved
arterial allografts.
Patients and Methods
During 1996–2000 we treated 45 patients, 38 men and
seven women, having arterial allografts for treatment
of graft infection. Patients had a mean age of 61 years
(range 40–80 years). The risk factors related to primary
disease are presented in Table 1. The most common
indication for the original aortic operation was
occlusive disease at the aorto-femoral level ðn ¼ 42Þ:
Other indications were an infrarenal abdominal aortic
aneurysm in two cases and a popliteal artery aneur-
ysm in one case. The primary procedures were as
follows: 32 aorto-bifemoral grafts, two aorto-femoral
grafts, five ilio-femoral grafts, three femoro-femoral
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cross-over grafts, two axillo-femoral grafts and one
popliteal graft. They were divided into intra- and
extra-abdominal grafts, groups I ðn ¼ 39Þ and II
ðn ¼ 6Þ, respectively.
The interval between primary implantation of the
vascular prosthetic grafts and development of signs of
infection ranged from 1 month to 12 years (mean 27
months). In 34 patients undergoing surgery in the
years 1996–1999, local procedures (debridement,
irrigating drainage or partial graft removal) were
performed with simultaneous revascularization with a
new vascular prosthetic graft implanted in situ. In the
majority of cases (23 out of 34) these procedures were
performed outside our institution. Clinical impression
of infection limited to the groin was the main
indication for these procedures. Unfortunately, in
every case recurrence of infection was observed
between 1 and 36 months, usually with a more
advanced stage of infection. In the remaining 11
patients, with original surgery 1999– 2000, more
radical initial treatment of infection was undertaken.
In all 11 cases CT scan showed involvement of the
entire graft. In all patients, stage III, IV or V infection
(Samson and Veith classification) was observed. The
clinical signs of vascular prosthetic graft infection of
these patients are presented in Table 2.
Six patients required emergency surgery because of
massive bleeding from aorto-enteric fistula in two
cases, septic shock in one case and groin hemorrhage
in three cases.
Material for bacteriology was obtained pre-opera-
tively from 23 patients with purulent fistula and from
five with groin abscess. Smears taken from regions
around the graft and parts of the removed grafts were
obtained intra-operatively in every patient.
Radical treatment consisted of total removal of the
graft in every case. Only in one patient, with very
extensive involvement of the iliac vessels and the
ureter, a 1 cm fragment of ilio-femoral graft, together
with the proximal anastomosis could not be removed.
In the cases of groin fistula or abscess, all infected
tissues were debrided. The channels, which remained
after removal of the arms of the graft, and the bed
remaining after removal of the main body of the graft,
were irrigated with povidone iodine. The tissues
surrounding the graft were not removed.
In all cases simultaneous restoration of the blood
flow to the lower extremities was performed with in
situ ðn ¼ 43Þ or extra-anatomic (n ¼ 2; femoro-femoral
cross-over bypass) implantation of an arterial allo-
graft. The latter was performed in patients with
retroperitoneal pelvic abscess after removal of infected
ilio-femoral grafts in who, either because of poor
general status or difficult local conditions, in situ
implantation of an arterial allograft was not possible.
In four patients with true aorto-enteric fistula the
defect in the intestinal wall was repaired with a double
layer closure after debriding the wound edges and the
allograft was covered with a flap of the omentum. In
the patient with the infected popliteal graft, vascular
reconstruction was carried out with a segment of
allogenic femoral artery.
Material for the arterial allografts came from
multiple-organ donors, in whom a distal part of
abdominal aorta together with iliac and femoral
vessels was procured. Within 12 h of procurement,
the vessels were assessed both macroscopically and
microbiologically. They were then frozen in an RPMI
1640 solution in the presence of 15% DMSO at the
controlled rate of 1 8C/min until reaching 280 8C.
Frozen allografts were preserved for up to 6 months in
liquid nitrogen. They were thawed in a water bath at a
temperature of 37 8C directly before implantation.
Negative microbiological test results were necessary
for use of the allograft.
Because of the limited availability of allografts,
matching blood compatibility between recipient and
donor was not possible in all cases. Thirty-eight
cryopreserved arterial allografts were ABO compati-
ble with the recipient and seven of them were
mismatched. None of the patients received any
immunosuppressive therapy.
Table 1. Comorbidities in a group of 45 patients with infected
prosthetic vascular graft
Comorbidity N
Ichaemic heart disease 10
Hypertension 8
History of myocardial infarction 6
Tuberculosis 5
History of neoplasm 5
Diabetes 4
Peptic ulcer 4
Anaemia 2
History of stroke 2
Table 2. Clinical presentation of all 45 patients with infected
prosthetic vascular graft
Clinical signs N
Purulent groin fistula 23
Groin abscess 7
Bleeding from groin fistula 7
Fever 7
Rupture of femoral anastomosis 5
Acute limb ischaemia 4
Severe gastroduodenal bleeding 4
Septic shock 3
Purulent fistula in abdominal wall 2
Microembolisation 2
Retroperitoneal abscess 2
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All patients received antibiotics intravenously from
the day of allograft implantation until the 7–10th
postoperative day. Thereafter oral antibiotics were
continued for the next 4–6 weeks. All patients gave
informed consent prior to the implantation of the
allograft.
All patients have been under regular follow-up
consisting of clinical and ultrasonographic examin-
ation every 3 months. Follow-up ranged from 30 to 78
months.
Statistical analysis
Primary graft patency was determined as the initial
episode of graft failure (thrombosis, stenosis, anasto-
moses disruption). Secondary patency was calculated
as a composite patency and included patency after
thrombectomy and after graft revision/replacement.
Long-term primary and secondary graft patency, limb
salvage, and survival were determined with the
Kaplan–Meier life table methods.
Results
Bacteriology
A positive culture was obtained in 43 patients (95%).
Mixed bacterial strains were found in 10 cases and
fungal infection was found in two cases. Staphylococci
were the most frequently cultured bacteria (74% of
patients), with MRSA accounting for 45% of cases.
Detailed data regarding cultured bacteria are pre-
sented in Table 3.
Early postoperative results
Directly after thawing, the presence of transverse, full-
thickness cracks of the allografts, localised mainly in
the area of bifurcation was observed in four allografts.
The cracks were repaired with continuous Prolene 6-0
suture. Repetitive cracking of the allograft, resulting in
bleeding from the distal anastomotic region, was
observed only in one case following in situ implan-
tation. In this case further allograft replacement was
required.
Six patients (13%) died within the first 30 post-
operative days. Three of them died because of sepsis.
In two, signs of septic shock were present before
surgery. Despite removal of the source of infection, the
sepsis could not be controlled and these patients
developed multiple organ dysfunction and died in the
first and third postoperative days. In the third patient,
sepsis developed as a consequence of gangrene of the
left leg, after the patient refused consent for amputa-
tion. In two patients with aorto-enteric fistula, massive
haemorrhage into the peritoneal cavity and duode-
num occurred in the seventh and 21st postoperative
day, respectively. In one of these two patients an
extensive retroperitoneal haematoma with dehiscence
of proximal anastomosis was found intra-operatively.
Autopsy performed in the second patient revealed
extensive suppuration in the retroperitoneal space,
with disruption of the proximal anastomosis and
reformation of the aorto-enteric fistula. The early
mortality in patients with secondary aorto-enteric
fistula appeared higher than in other patients (50%
versus 9.8%, p ¼ 0:08 Fisher’s exact test). The cause of
death of the sixth patient was myocardial infarction.
Three out of six (50%) patients operated on as an
emergency died within the first 30 post-operative
days.
In eight patients the groin wound did not heal
primarily. In five of them haemorrhage from the
femoral anastomosis occurred and further surgical
intervention was required. In three of them a sartorius
muscle flap was used to cover the anastomosis,
leading to wound healing in two cases. In three
patients ligation of the arm of the allograft was
required. The cultured microorganisms in these three
cases were Morganella morganii, Proteus mirabilis and
mixed flora: Pseudomonas aeruginosa, Staphylococcus
aureus (MRSA) and Candida albicans, respectively.
Prior to the implantation of the allograft, the latter
patient underwent several gastrointestinal operations
together with stoma formation. Above knee amputa-
tion was required in two patients because of unrecon-
structible critical limb ischaemia.
Thrombosis of the allograft was observed in two
Table 3. Organisms grown from infected prosthetic graft in all 45
patients
Organism No.
Staphylococcus coag þ 18
Staphylococcus aureus 10
Staphylococcus epidermidis 5
Streptococcus 7
Escherichia coli 4
Gemella morbillarium/haemolysis 4
Morganella 2
Pseudomonas aeruginosa 1
Proteus mirabilis 1
Serratia marcescens 1
Klebsiella oxytocea 1
Clostridium tritium 1
Candida albicans 2
No organisms detected 2
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patients. Thrombectomy performed on the second and
sixth post-operative days, respectively, with a venous
patch angioplasty of the distal anastomosis in one
patient and a femoro-popliteal bypass graft in the
other, resulting in patent allografts in both cases.
Two of 39 surviving patients had non-allograft
related complications: lymph drainage from the groin
wound and injury of the femoral nerve. Patency of the
allografts was demonstrated in 37 patients prior to
discharge from the hospital. In the remaining two
patients, in whom ligation of one of the arms of
allograft had been performed, the residual part of the
allograft (main body and contralateral arm) was also
patent. The mean hospital stay was 18 ^ 9 days.
Early post-operative complications in groups I and
II are presented in Table 4.
Late results
Out of 39 patients discharged from the hospital, one
was lost to follow-up. Two patients died, one of
myocardial infarction at 14 months and one of retro-
peritoneal haemorrhage at 21 months after allograft
implantation. The latter patient was one of four who
originally presented to our department with second-
ary aorto-enteric fistula.
In 10 patients, progressive stenosis of the distal
anastomosis was observed. Haemodynamically criti-
cal stenosis was treated by percutaneous angioplasty
in one patient and venous patch-angioplasty in
another patient. In three patients, thrombosis of the
arm of the allografts was observed with one patient
having sequential thrombosis of both arms. In these
three patients, three thrombectomies and one amputa-
tion were performed.
Two patients required implantation of prosthetic
grafts. In one patient, because of thrombosis of the
femoro-femoral crossover allograft, an aorto-bifemoral
Dacron graft was implanted. Though implantation of a
new prosthetic graft was performed 11 months after
removal of the infected graft and implantation of
allograft, signs of infection of the new graft emerged 2
months later and a further in situ arterial allograft
implantation was required. The bacteriology revealed
the same bacteria that were present in the primary
infection (S. hominis, S. haemoliticus). In the second
patient, a giant pseudo-aneurysm occurred 21 months
after implantation of ilio-femoral allograft. This was
managed with an ilio-femoral PTFE graft, but 3
months later, a purulent groin fistula developed and
bacteriology revealed the same bacteria that were
present in the primary infection (S. epidermidis). In two
patients, mechanical ileus developed and in one, an
external intestinal fistula developed between intestine
and the channel remaining after removal of the graft.
Late complications in groups I and II are presented in
Table 4.
Altogether during the entire follow-up, ranging
from 30 to 78 months, eight (17.7%) out of 45 operated
patients died. Complications related directly to graft
infection or implantation of the allograft were the
cause of death in six cases. The most frequent cause of
death was disruption of proximal anastomosis in
patients with secondary aorto-enteric fistula (three
out of four died). Three above knee amputations were
performed (8.1%). Primary patency of the allograft
was 87.1 and 81.1% after 1 month and 3 years,
respectively. Secondary patency rate was 91.9% at
both 1 month and 3 years. The overall survival rate
was 86.7 and 82.3% after 1 month and 3 years,
respectively. The graft failure free survival rate was
82 and 61% after 1 month and 3 years, respectively.
Altogether, four out of six (66.7%) patients operated on
as an emergency died, three of them within the first 30
post-operative days. The overall mortality rate in the
elective surgery group was 10.8%. Detailed data
concerning survival as well as primary and secondary
patency in groups I and II are presented in Table 5.
Table 4. Early and late complications in patients from group I (intra-abdominal graft) and II (extra-abdominal graft)
Post-operative
period
Event Intra abdominal ðn ¼ 39Þ Extra-abdominal ðn ¼ 6Þ
Early—30 days Fatal complications Sepsis (3), recurrent aorto-enteric fistula (1),
bleeding from proximal anastomosis (1),
myocardial infarction (1)
Non-fatal complications Recurrent bleeding from distal anastomosis
(2), graft thrombosis (1)
Recurrent bleeding from distal anastomosis
(3), graft thrombosis (1)
Amputations Above knee amputation (2)
Late Fatal complications Recurrent aorto-enteric fistula (1) Myocardial infarction (1)
Non-fatal complications Stenosis of anastomosis (7), graft thrombosis
(2), groin pseudoaneurysm (1)
Stenosis of anastomosis (3), graft thrombosis
(1)
Amputations Above knee amputation (1)
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Discussion
Although the policy of restoration of blood flow to
the lower extremities after removal of infected
vascular prosthetic grafts is obvious, the choice of
technique is still a matter of discussion. One of the
frequently used techniques is extra-anatomical pros-
thetic bypass. This reduced the mortality rate to 13–
30% and major amputation rate to 18–24%. Unfor-
tunately, these procedures are associated with
several problems. The construction of a distal
anastomosis requires access to patent and inflam-
matory-free segment of artery. Taking into account
that 70% of infections are localized in the groin,
such a bypass needs to be extended to the popliteal
or even tibial arteries, thus compromising the blood
flow within the bypass graft itself. This may be the
main cause of thrombosis of these bypasses, leading
to the low reported 5-year patency rate of 19%.4
Intra-operative contamination of the graft, or its
implantation in the infected region, results in
recurrence of graft infection in 10–20% of cases.2,5
The extremely dangerous complication of extra-
anatomic reconstruction is disruption of the aortic
stump, which occurs in 6–10% of patients.7 These
problems usually limit the indications for extra-
anatomical reconstruction to patients in poor general
condition, with sepsis and a short-life expectancy.8
It appears that in situ reconstruction can eliminate
many of the disadvantages. The concept of aortic
reconstruction with in situ PTFE grafts has relatively
few supporters. Jacobs implanted in situ PTFE grafts in
patients with negative bacteriology and achieved good
results in all cases.9 However, negative bacteriology
results do not completely exclude the presence of
bacteria around the graft. Moreover, no correlation
was found between negative results of cultures and
survival in patients with infected vascular prosthetic
grafts.4 The negative cultures, found in 5% of our
patients, occur in up to 30% of patients with infected
vascular prosthetic grafts and may be the result of
long-lasting antibiotic therapy in perioperative
period4 or infection with coagulase-negative Staphy-
lococci.10
Although early studies indicated that the rifampi-
cin,11 silver or triclosan12 impregnated grafts in the
treatment of limited vascular prosthetic graft infec-
tions, larger studies have shown that the results of
treatment with rifampicin impregnated grafts are
unsatisfactory in cases of MRSA, fungi and rifampicin
resistant Staphylococcus epidermidis. Collectively these
pathogens were responsible for the 16–35% mortality
rate in studies of Bandyk11 and Hayes.13 There is no
correlation between concentration of the antibiotic
released from the graft, or even its presence, and risk
of re-infection in MRSA cases.14 Therefore the indi-
cations for implantation of rifampicin-impregnated
grafts are limited to primary prophylaxis against
infection.
Early clinical experience, in the 1970s, using arterial
allografts for aortic reconstruction in an infected field,
were unsatisfactory. Szilagyi reported a 37% mortality
rate and a 33% amputation rate.1 The use of fresh
allografts was associated with early and late rupture of
the wall, aneurysmal dilatation and thrombosis.15
These complications probably resulted from preser-
vation of antigenicity by fresh allografts, causing
abundant infiltration of macrophages and plasmatic
cells with subsequent release of proteolytic enzymes
causing the degeneration of elastin and collagen
fibres.15 The introduction of cryopreservation tech-
niques led to improving results, the mortality rate
decreasing to 13–25% and amputation rate decreasing
to 5%.16,17 The early mortality rate in our study, 13%, is
consistent with the other reports, but varied according
to localisation of the infected graft. As with other
studies, sepsis and disruption of the proximal anasto-
mosis were the most common causes of early post-
operative death. The signs of sepsis occur frequently in
patients operated on as an emergency, especially if
earlier they had developed signs of shock.18,19 This is a
strong evidence against a policy of local treatment,
instead of a total removal of the infected graft.
Mortality rates as high as 83% have been reported.18,20
Table 5. Mortality, survival and primary and secondary patency in patients from groups I (intra-abdominal graft) and II (extra-abdominal
graft)
Time after surgery Parameter Intra abdominal, n ¼ 39 (%) Extra-abdominal, n ¼ 6 (%)
30 days Mortality 6 (15%) 0%
Survival 33 (85%) 6 (100%)
Primary patency 35 (90%) 4 (67%)
Secondary patency 37 (95%) 5 (83%)
3 years Mortality 7 (18%) 1 (17%)
Survival 32 (82%) 5 (83%)
Primary patency 84% 60%
Secondary patency 95% 80%
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However, patients without aorto-enteric fistula had a
lower 9% mortality rate.18 One possible reason for the
high mortality rates is the presence of highly virulent
bacterial strains capable of long-term maintenance of
an inflammatory process in the retroperitoneal space.
The influence of irritating intestinal contents,
especially bile, on intestinal repair is another reason
that has been postulated.18 Autopsy of our patients
with reformation of aorto-enteric fistula showed an
extensive purulent process in the retroperitoneal
space, indicative of chronic inflammation caused by
mixed bacterial flora with a predominance of Gram-
negative bacteria. Covering the allograft with an
omental flap could not control this.
Complications related directly to the allograft
include ruptures of the allograft wall, segmental
dilatation and progressive thickening of the intima-
media complex leading to stenosis at the site of distal
anastomosis and subsequent thrombosis. Cryopreser-
vation has attenuated these complications.16 Preser-
vation of the allografts at a temperature of 4 8C or
freezing in the presence of cryoprotectant causes
exfoliation of endothelial cells.21 These preservation
techniques also decrease the number of smooth muscle
cells in the media.21 Together these alterations are
associated with a reduction in the clinical symptoms of
chronic rejection, without influence on mechanical
properties of the allografts.21 However, the beneficial
influence of cryopreservation on diminishing of
antigenicity of allografts has been questioned
recently.22 Therefore, matching donor and recipient
for ABO and HLA types is recommended.23 However
this is seldom possible, unless there is access to a well-
supplied tissue bank.
Despite regular follow-up with duplex-Doppler
ultrasonography, we did not observe aneurysmal
degeneration of the allograft in any of our patients.
In most allografts gradual thickening of intima-media
complex was observed, leading to a progressive
decrease in compliance of allograft wall. Both these
factors may have contributed to the stenosis of the
distal anastomosis found in 10 patients, three of whom
developed thrombosis of the allograft and two
required percutaneous angioplasty. A further decrease
in the incidence of thrombosis might be achieved with
regular ultrasonographic surveillance and early inter-
vention. In cases of allograft thrombosis, successful
thrombectomy can be performed as late as 2 months
after the event.
The transverse cracking of the allograft wall, which
we observed intra-operatively and in the early post-
operative period, can be caused by improper thawing
procedures. Experimental studies have proved that
cryopreservation keeps the structural features
unchanged.24 However, it is possible that cooling and
thawing procedures, even if there are cryoprotectants,
could cause graft damages like those we have observed.
Wassenaar et al. have reported that rapid thawing can
crack the vascular wall of homografts.25 They also
reported that cracking can be prevented by allowing the
graft to reach the temperature of about 2100 8C slowly,
before more rapid thawing in a 40 8C water bath.25
The question of permanent eradication of infection
after insertion of an allograft remains. Leseche et al.
report successful treatment of thrombosed or aneur-
ysmally dilated allografts with PTFE grafts.17 In two of
our patients, however, with Dacron or PTFE graft
implanted in place of thrombosed allograft, signs of re-
infection developed 2 and 3 months later. Though the
exchanged allografts had functioned well for 11 and 21
months after insertion, without any clinical and
radiological signs of infection, bacteriology revealed
the same bacteria as in the primary infection. In
addition, histopathology specimens of the implanted
allografts from deceased patients revealed the presence
of bacteria in the scar surrounding the graft. The number
of specimens for study is limited. Autopsy material does
indicate if any bacteria are remnants of infection or
results of contamination during autopsy and sampling.
In cases of extensive groin infiltration or for
re-operation in the area of femoral anastomoses, we
now routinely use sartorius muscle flap to cover the
anastomosis. Influenced by good results reported in
the literature,26,27 we also have started to use auto-
genous femoral veins for aorto-femoral reconstruction,
particularly in patients with aorto-enteric fistula.
Conclusions
Aortic allografts are useful in the treatment of infection
of major vascular prosthetic grafts. In the sub-group of
patients with aorto-enteric fistula there are numerous
complications and the use of allografts is questionable.
Patients with infection of the prosthetic graft should be
promptly assessed for removal of the graft, since
results of elective surgery are much better than results
of emergency procedures. Problems with the perma-
nent eradication of infection indicate that all further
surgical procedures involving allografts should be
performed with biological materials only.
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